ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. is beginning to pull back the curtain on its R&D strategy under Roger Perlmutter, who left Amgen last year to head Merck’s research operations. The drug company will lessen its traditional focus on in-house research and increasingly look for discoveries made outside its own labs. As such, Merck will establish innovation hubs in Boston, the San Francisco Bay Area, London, and Shanghai as a means of accessing cutting-edge science from academic experts and biotech firms. The news of Merck’s shift was first reported in the Wall Street Journal; Merck confirmed the story’s details but declined to offer further comment.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X